<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="article-commentary" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101684512</journal-id>
<journal-id journal-id-type="pubmed-jr-id">45354</journal-id>
<journal-id journal-id-type="nlm-ta">J Neurol Neuromedicine</journal-id>
<journal-title-group>
<journal-title>Journal of neurology &amp; neuromedicine</journal-title>
</journal-title-group>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29152613</article-id>
<article-id pub-id-type="pmc">5690562</article-id>
<article-id pub-id-type="manuscript">NIHMS893471</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Commentary: Target Intestinal Microbiota to Alleviate Disease Progression in
Amyotrophic Lateral Sclerosis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Sun</surname>
<given-names>Jun</given-names>
</name>
<aff id="A1">Department of Medicine, University of Illinois at Chicago 840 S Wood Street,
Room 704 CSB, MC716, USA</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="FN1"><label>*</label>Correspondence: Associate Professor, Division of Gastroenterology
and Hepatology, Department of Medicine, University of Illinois at Chicago, 840 S, Wood
Street, Room 704 CSB, MC716, USA, Tel: 312-996-5020,
<email>junsun7@uic.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>28</day>
<month>7</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>12</day>
<month>6</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>16</day>
<month>11</month>
<year>2017</year>
</pub-date>
<volume>2</volume>
<issue>6</issue>
<fpage>13</fpage>
<lpage>15</lpage>
<permissions>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This article is distributed under the terms of the Creative Commons Attribution
4.0 International License</license-p>
</license>
</permissions>
<self-uri xlink:href="http://www.jneurology.com/articles/commentary-target-intestinal-microbiota-to-alleviate-disease-progression-in-amyotrophic-lateral-sclerosis.html"></self-uri>
<related-article ext-link-type="pmcid" id="ra1" related-article-type="commentary-article" xlink:href="5344195" xlink:type="simple"></related-article>
</article-meta>
</front>
<body>
<p id="P1">Amyotrophic lateral sclerosis (ALS), also called Lou Gehrig’s disease, is a
neuromuscular disease characterized by a progressive death of motor neurons and muscle
atrophy. Most ALS patients die within 5 years of disease onset. Currently, treatment with the
US Food and Drug Administration (FDA) approved drug, Riluzole, merely extends the
patient’s life span for a few months. For the second time in history, FDA has approved
a new drug edaravone specifically for the treatment of ALS in May 8, 2017. There is still a
need to develop new treatments for alleviating the disease progression and improving the lives
of ALS patients.</p>
<p id="P2">The gut is considered the second brain of the human being. It contains roughly the
same amount of neurons as the spinal cord. The integrative function of gut-secreted hormones
plays an important role in human physiology and pathophysiology. Emerging evidence has shown
that altered intestinal homeostasis and microbiome contribute to a variety of neurological
diseases, including autism and Parkinson’s disease<sup><xref ref-type="bibr" rid="R1">1</xref>–<xref ref-type="bibr" rid="R3">3</xref></sup>. However, very little is
known about the roles of intestine and microbiome in ALS. Our lab is the first to discover the
link between intestinal homeostasis and the disease progression in an ALS mouse model
G93A<sup><xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R5">5</xref></sup>.</p>
<p id="P3">Our recent study, entitled “<italic>Target Intestinal Microbiota to Alleviate
Disease Progression in Amyotrophic Lateral Sclerosis</italic>”, has revealed a
promising link of dysbiosis and aberrant intestine to disease progression in an ALS mouse
model with overexpression of human mutation gene superoxide dismutase 1
(<italic>SOD1<sup>G93A</sup></italic>)<sup><xref ref-type="bibr" rid="R4">4</xref></sup>.
Mouse models expressing ALS-linked SOD1 mutations (e.g. SOD1<sup>G93A</sup>) effectively
recapitulate many features of the human disease, and have been extensively used to investigate
pathogenic mechanisms of ALS<sup><xref ref-type="bibr" rid="R6">6</xref></sup>. The
SOD1<sup>G93A</sup> mice show dysbiosis with reduced butyrate-producing bacteria<sup><xref ref-type="bibr" rid="R5">5</xref></sup>. These changes occur in young G93A mice before ALS
onset. In the current study, we hypothesize that restoring microbiome and intestinal
homeostasis delays disease onset and progression of ALS. After being fed with the beneficial
bacteria product butyrate, G93A mice exhibited a delay in the onset of ALS symptoms and a
prolonged life span.</p>
<p id="P4">Bacterial products short chain fatty acids (SCFA) provide energy for the colonocytes
and exert beneficial effects in the gut<sup><xref ref-type="bibr" rid="R7">7</xref></sup>.
Butyrate (a SCFA) and butyrate-producing bacteria are thought to have beneficial effects to
the host through anti-inflammatory properties<sup><xref ref-type="bibr" rid="R8">8</xref></sup>. In our study, treatment with butyrate delays disease onset in the
SOD1<sup>G93A</sup> mouse. Butyrate synthesis by anaerobic bacteria can occur via
butyryl-coenzyme A (CoA): acetate CoA-transferase<sup><xref ref-type="bibr" rid="R9">9</xref></sup>. In our study, oral 2% sodium butyrate treatment for 2.5 months
restores the physiological CoA enzyme levels (comparable to wild type mice) in pre-symptomatic
SOD1 mice. Interestingly, our unpublished data also show that ALS patients had significantly
low butyrate and total SCFA levels.</p>
<p id="P5">Intestinal epithelia of SOD1<sup>G93A</sup> mice have a disrupted tight junction
structure accompanied with increased intestinal permeability<sup><xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R5">5</xref></sup>. Paneth cells are
specialized intestinal epithelial cells that regulate the host-bacterial interactions in
gut<sup><xref ref-type="bibr" rid="R10">10</xref>,<xref ref-type="bibr" rid="R11">11</xref></sup>. The abnormal Paneth cells were significantly increased in the
SOD1<sup>G93A</sup> mice. We found that butyrate, restored some of the intestinal defects
and corrected dysbiosis in the ALS mice. At the cellular level, butyrate treatment decreased
abnormal Paneth cells. Moreover, butyrate reduced aggregation of the G93A-SOD1 mutated protein
in small intestine and colon of ALS mice.</p>
<p id="P6">Based on the current data, the improvements due to pre-symptomatic butyrate treatment
include improving the intestinal barriers, correcting dysbiosis, restoring Paneth cells, and
reducing aggregation of the G93A-SOD1 mutated protein in ALS mice, thus slowing down the
progression of disease. This study focuses on investigating the novel role of gut microbiome
and intestinal functions in ALS and exploring potential therapeutic targets for ALS by
restoring healthy host-bacterial interactions. It highlights the complex roles of microbial
and intestinal homeostasis that contribute to the neuromuscular dysfunction in ALS. It has
provided insight into targeting intestinal functions and microbiome that may slow down ALS
pathogenesis.</p>
<p id="P7">Sodium phenylbutyrate has been widely considered as an inhibitor of histone
deacetylases (HDAC)<sup><xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R13">13</xref></sup>. It is used in the ALS mice through intraperitoneal
injection<sup><xref ref-type="bibr" rid="R14">14</xref></sup> and tested in ALS patients
for safety<sup><xref ref-type="bibr" rid="R15">15</xref></sup>. Sodium phenylbutyrate can
contribute to gut function through modulation of tight junctions<sup><xref ref-type="bibr" rid="R16">16</xref></sup>. Therefore, the proactive role of sodium phenylbutyrate in
ALS could also through restoring intestinal permeability. Understanding the molecular
mechanism for the direct beneficial roles of butyrate on neuromuscular dysfunction in ALS is
an ongoing study in our research team. A HDAC inhibitor could be used as a control for its
effects on intestinal microbiome.</p>
<p id="P8">Most ALS cases are sporadic (SALS), with about 10% being familial (FALS).
Both SALS and FALS manifest similar pathological and clinical phenotypes, suggesting that
different initiating causes lead to a mechanistically similar neurodegenerative pathway. A
fraction of FALS are associated with mutations in the superoxide dismutase gene
<italic>SOD1</italic><sup><xref ref-type="bibr" rid="R17">17</xref></sup>. It may be
interesting to evaluate other ALS experimental models, i.e. transactive response DNA binding
protein (TDP)-43 mouse model).</p>
<p id="P9">In SALS, there is study reported the increased circulating bacterial
lipopolysaccharides (LPS) and systemic immune activation<sup><xref ref-type="bibr" rid="R18">18</xref></sup>. Our unpublished data evaluates the gastrointestinal health and
microbiome profile of patients with heterogenous motor neuron syndromes. We observed decreased
diversity, altered ratio of two major bacterial members: <italic>Firmicutes</italic> and
<italic>Bacteroidetes</italic>, and low butyrate in human ALS. Only one patient did not have
a low <italic>Firmicutes</italic> / <italic>Bacteroidetes</italic> ratio. Further, our
unpublished study has shown elevated intestinal inflammation in ALS patients. Along these
lines, ALS G93A mice showed abnormal intestinal microbiome, in which butyrate-producing
bacteria (<italic>Butyrivibrio</italic> Fibrisolvens) were reduced.
<italic>Firmicutes</italic> make up the largest portion of the mouse and human gut
microbiome<sup><xref ref-type="bibr" rid="R19">19</xref></sup>. The division
<italic>Firmicutes</italic> as part of the gut flora has been shown to be involved in energy
resorption and obesity<sup><xref ref-type="bibr" rid="R20">20</xref>,<xref ref-type="bibr" rid="R21">21</xref></sup>. <italic>Fimicutes Peptostreptococus</italic>, which was
low in ALS mice<sup><xref ref-type="bibr" rid="R5">5</xref></sup>, was also enhanced after
butyrate treatment. Several clinical studies have demonstrated the safety for butyrate or its
derivative in human subjects<sup><xref ref-type="bibr" rid="R22">22</xref></sup>. Thus, our
study with oral sodium butyrate treatment in the G93A mice may be applied to both SALS and
FALS for translation to clinical therapy.</p>
<p id="P10">Humans have coevolved with their microbes over thousands of years, but this
relationship, is now being dramatically affected by shifts in the collective human microbiome
resulting from changes in the environment and societal norms<sup><xref ref-type="bibr" rid="R23">23</xref></sup>. Mismatches in host-microbe relationships lead to
homeostatic chaos, likely explaining the increased incidence and prevalence of many disorders
that have merged with alarming frequency in the modern age. We still lack research on the
early intestinal issue from ALS patients. ALS research need learn from the experience and
lessons in the filed of inflammatory bowel diseases, obesity, and other chronic diseases. A
better understanding of human microbiome would facilitate the development of targeted
interventions to control the progression of ALS.</p>
</body>
<back>
<ack id="S1">
<p>We would like to acknowledge the NIDDK/National Institutes of Health grant R01 DK105118 to
Jun Sun.</p>
</ack>
<ref-list>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsiao</surname>
<given-names>EY</given-names>
</name>
<name>
<surname>McBride</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Hsien</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Microbiota modulate behavioral and physiological abnormalities associated
with neurodevelopmental disorders</article-title>
<source/>Cell
          <year>2013</year>
<volume>155</volume>
<fpage>1451</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="pmid">24315484</pub-id>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Forsyth</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Shannon</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Kordower</surname>
<given-names>JH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased intestinal permeability correlates with sigmoid mucosa
alpha-synuclein staining and endotoxin exposure markers in early Parkinson’s
disease</article-title>
<source/>PLoS One
          <year>2011</year>
<volume>6</volume>
<fpage>e28032</fpage>
<pub-id pub-id-type="pmid">22145021</pub-id>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sampson</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Debelius</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Thron</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of
Parkinson’s Disease</article-title>
<source/>Cell
          <year>2016</year>
<volume>167</volume>
<fpage>1469</fpage>
<lpage>1480</lpage>
<fpage>e12</fpage>
<pub-id pub-id-type="pmid">27912057</pub-id>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>YG</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Target Intestinal Microbiota to Alleviate Disease Progression in
Amyotrophic Lateral Sclerosis</article-title>
<source/>Clin Ther
          <year>2017</year>
<volume>39</volume>
<fpage>322</fpage>
<lpage>336</lpage>
<pub-id pub-id-type="pmid">28129947</pub-id>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>YG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Leaky intestine and impaired microbiome in an amyotrophic lateral sclerosis
mouse model</article-title>
<source/>Physiological reports
          <year>2015</year>
<fpage>3</fpage>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McGoldrick</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Joyce</surname>
<given-names>PI</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>EM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rodent models of amyotrophic lateral sclerosis</article-title>
<source/>Biochim Biophys Acta
          <year>2013</year>
<volume>1832</volume>
<fpage>1421</fpage>
<lpage>36</lpage>
<pub-id pub-id-type="pmid">23524377</pub-id>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>YG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Leaky intestine and impaired microbiome in an amyotrophic lateral sclerosis
mouse model</article-title>
<source/>Physiol Rep
          <year>2015</year>
<fpage>3</fpage>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>YG</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intestinal epithelial vitamin D receptor deletion leads to defective
autophagy in colitis</article-title>
<source/>Gut
          <year>2015</year>
<volume>64</volume>
<fpage>1082</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="pmid">25080448</pub-id>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duncan</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Barcenilla</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>CS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Acetate utilization and butyryl coenzyme A (CoA):acetate-CoA transferase in
butyrate-producing bacteria from the human large intestine</article-title>
<source/>Appl Environ Microbiol
          <year>2002</year>
<volume>68</volume>
<fpage>5186</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="pmid">12324374</pub-id>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Vitamin D receptor regulates autophagic activity through
ATG16L1</article-title>
<source/>Autophagy
          <year>2016</year>
<volume>12</volume>
<fpage>1057</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">26218741</pub-id>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cadwell</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>SL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A key role for autophagy and the autophagy gene Atg16l1 in mouse and human
intestinal Paneth cells</article-title>
<source/>Nature
          <year>2008</year>
<volume>456</volume>
<fpage>259</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="pmid">18849966</pub-id>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davie</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Inhibition of histone deacetylase activity by butyrate</article-title>
<source/>The Journal of nutrition
          <year>2003</year>
<volume>133</volume>
<fpage>2485S</fpage>
<lpage>2493S</lpage>
<pub-id pub-id-type="pmid">12840228</pub-id>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cuadrado Tejedor</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ricobaraza</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Torrijo</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects
and reverses the Alzheimer s disease-like phenotype of a commonly used mouse
model</article-title>
<source/>Current pharmaceutical design
          <year>2013</year>
<volume>19</volume>
<fpage>5076</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="pmid">23448463</pub-id>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ryu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Camelo</surname>
<given-names>SI</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sodium phenylbutyrate prolongs survival and regulates expression of
anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice</article-title>
<source/>J Neurochem
          <year>2005</year>
<volume>93</volume>
<fpage>1087</fpage>
<lpage>98</lpage>
<pub-id pub-id-type="pmid">15934930</pub-id>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cudkowicz</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Andres</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Macdonald</surname>
<given-names>SA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Phase 2 study of sodium phenylbutyrate in ALS</article-title>
<source/>Amyotroph Lateral Scler
          <year>2009</year>
<volume>10</volume>
<fpage>99</fpage>
<lpage>106</lpage>
<pub-id pub-id-type="pmid">18688762</pub-id>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bordin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>D’Atri</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Guillemot</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Histone deacetylase inhibitors up-regulate the expression of tight junction
proteins</article-title>
<source/>Mol Cancer Res
          <year>2004</year>
<volume>2</volume>
<fpage>692</fpage>
<lpage>701</lpage>
<pub-id pub-id-type="pmid">15634758</pub-id>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pasinelli</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>RH</given-names>
</name>
</person-group>
<article-title>Molecular biology of amyotrophic lateral sclerosis: insights from
genetics</article-title>
<source/>Nat Rev Neurosci
          <year>2006</year>
<volume>7</volume>
<fpage>710</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="pmid">16924260</pub-id>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Gascon</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Circulating endotoxin and systemic immune activation in sporadic
amyotrophic lateral sclerosis (sALS)</article-title>
<source/>J Neuroimmunol
          <year>2009</year>
<volume>206</volume>
<fpage>121</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="pmid">19013651</pub-id>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ley</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Peterson</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>JI</given-names>
</name>
</person-group>
<article-title>Ecological and evolutionary forces shaping microbial diversity in the human
intestine</article-title>
<source/>Cell
          <year>2006</year>
<volume>124</volume>
<fpage>837</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="pmid">16497592</pub-id>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ley</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Turnbaugh</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Microbial ecology: human gut microbes associated with
obesity</article-title>
<source/>Nature
          <year>2006</year>
<volume>444</volume>
<fpage>1022</fpage>
<lpage>3</lpage>
<pub-id pub-id-type="pmid">17183309</pub-id>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ley</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Backhed</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Turnbaugh</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Obesity alters gut microbial ecology</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2005</year>
<volume>102</volume>
<fpage>11070</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">16033867</pub-id>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vernia</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Monteleone</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Grandinetti</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Combined oral sodium butyrate and mesalazine treatment compared to oral
mesalazine alone in ulcerative colitis: randomized, double-blind, placebo-controlled
pilot study</article-title>
<source/>Digestive diseases and sciences
          <year>2000</year>
<volume>45</volume>
<fpage>976</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="pmid">10795763</pub-id>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>EB</given-names>
</name>
</person-group>
<article-title>Exploring gut microbes in human health and disease: Pushing the
envelope</article-title>
<source/>Genes Dis
          <year>2014</year>
<volume>1</volume>
<fpage>132</fpage>
<lpage>139</lpage>
<pub-id pub-id-type="pmid">25642449</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>